Bristol-Myers (BMY) volatility flat at 20 into metastatic melanoma data
Tweet Send to a Friend
Bristol-Myers (NYSE: BMY) Ipilimumab 2nd line metastatic melanoma PDUFA is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
